NCT02747342View on ClinicalTrials.gov

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2020

Conditions
NeoplasmProstate Cancer
Interventions
DRUG

SHR3680; SHR3162

"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."

Trial Locations (6)

2050

Chris O'Brien Lifehouse, Camperdown

2145

Westmead Hospital, Sydney

2170

Liverpool Hospital, Liverpool

2217

St George Hospital, Kogarah

2640

Border Medical Oncology, Albury

4101

Icon Cancer Centre, South Brisbane

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT02747342 - A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | Biotech Hunter | Biotech Hunter